semaglutide receptor PDB-101: Molecule of the Month: GLP-1 Agonists Incretin & Hormone Receptor Agonists

Traditional approaches just werent working for me

For patients without diabetes using Wegovy for weight management: Routine blood glucose monitoring is not typically required , as hypoglycaemia risk is low Patients should be counselled about maintaining adequate nutritional intake despite appetite suppression Report any symptoms suggestive of hypoglycaemia (tremor, sweating, confusion) to their healthcare provider Annual HbA1c testing may be appropriate for those with prediabetes or metabolic syndrome For patients with type 2 diabetes on combination therapy: Self-monitoring of blood glucose (SMBG) frequency should be individualised based on hypoglycaemia risk Those on insulin or sulphonylureas should monitor more frequently, particularly during Wegovy initiation and dose escalation Continuous glucose monitoring (CGM) may be considered for high-risk individuals or those with impaired awareness, in line with NICE and NHS England access criteria Medication review and adjustment sulphonylurea and insulin doses often require reduction when starting GLP-1 therapy

The clinical relationship is strong too: You see the same provider every time, and the level of detail in my consultation was the best Ive experienced across all clinics Ive reviewed

Examples: CJC1295 Ipamorelin Sermorelin Tesamorelin Supports metabolism, body composition, and performance